MedTrace Logo

Evidence-based Stimulation Trial With Human rFSH in Europe and Rest of World 2

NCT01956123 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 513

Last updated 2023-09-06

Study results available
· View outcomes & findings →

Summary

This trial investigates the immunogenicity of FE 999049 in repeated cycles.

Conditions

Interventions

DRUG

Follitropin Delta (FE 999049)

DRUG

Follitropin Alfa (GONAL-F)

Sponsors & Collaborators

  • Ferring Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Clinical Development Support · Ferring Pharmaceuticals

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-03-26
Primary Completion
2015-05-31
Completion
2017-01-03

Countries

  • Belgium
  • Brazil
  • Canada
  • Czechia
  • Denmark
  • France
  • Italy
  • Poland
  • Russia
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01956123 on ClinicalTrials.gov